Overview
- 6 public-safe observations are available for this inspection.
- 2 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
27 Apr 2018
21 CFR 820.20(c)
Management review - defined interval, sufficient frequency
Cited by Yehualashe A Gessesse, Yehualashet A Gessesse
27 Apr 2018
21 CFR 820.20(c)
Management review - defined interval, sufficient frequency
Cited by Yehualashe A Gessesse, Yehualashet A Gessesse
27 Apr 2018
21 CFR 820.20(c)
Management review - Lack of or inadequate procedures
Cited by Yehualashe A Gessesse, Yehualashet A Gessesse
27 Apr 2018
21 CFR 820.20(c)
Management review - Lack of or inadequate procedures
Cited by Yehualashe A Gessesse, Yehualashet A Gessesse
27 Apr 2018
21 CFR 820.22
Quality Audits - defined intervals
Cited by Yehualashe A Gessesse, Yehualashet A Gessesse
Inspected site
DTDane TechnologiesMaple Grove, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 820.20(c) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 820.22 | Cited across public-safe Form 483 observations | 2x |
Full 483 report
Get the verbatim text of all 6 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere